Idiopathic Pulmonary Fibrosis
Conditions
Keywords
Homecare patient support
Brief summary
Homecare patient support program especially designed for covering IPF patient needs, implemented for 12 months, for improving quality of life
Detailed description
The proposed comprehensive IPF home care programme consists of: 1) improving patient's quality of life (autonomy, activity, emotional well-being and symptoms), 2) reducing the number and severity of side effects associated with the anti-fibrotic drug, 3) reducing the number of hospitalisations attributable to the disease, and 4) providing a rapid response to any problem associated with the disease (after diagnosis or progression) that may cause distress or require early action.
Interventions
COMBINATION_PRODUCTComprehensive patient support program (educational, physiotherapy, nutritional, emotional)
Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
Sponsors
Institut d'Investigació Biomèdica de Bellvitge
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Minimal intervention study, pre- and post- supportive care effects on quality of life
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* IPF patients with FVC \> 50% and DLCO \> 30%, in whom pharmacological treatment with nintedanib was started at least one month before the start of the programme.
Exclusion criteria
* Hospitalised patients or those who have been hospitalised in the previous month, due to any kind of respiratory exacerbation or due to any other respiratory cause. * Patients who are under home care controls (PADES) as this implies an advanced stage of the disease (forced vital capacity \[FVC\] less than 50% and the diffusion capacity of the lungs for carbon monoxide \[DLCO\] less than 30%) or, patients thathave a lack of autonomy due to comorbidities or respiratory failure * Patients diagnosed in incipient phase who have neither symptoms nor limitation in their usual activities. * Patients who have suffered any other life-threatening disease in the last 2 years, such as cancer or uncontrolled ischaemic heart disease. * Inability to understand the information given to the patient, relating to the legal aspects of the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Qulity of life | 12 months | K-BILD score (global and by domains) |
Countries
Spain
Outcome results
None listed